Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Debled

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Cancers|February 25, 2023
Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational StudyHélène François-Martin, Audrey Lardy-Cléaud, Barbara Pistilli, et al.
International Journal of Cancer|September 26, 2022
Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world databaseAudrey Mailliez, Veronique D'Hondt, Amelie Lusque, et al.
Therapeutic Advances in Medical Oncology|March 3, 2022
Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME databaseMarcela Carausu, Matthieu Carton, Luc Cabel, et al.
Ebiomedicine|May 8, 2024
Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trialSylvie Giacchetti, Enora Laas, Thomas Bachelot, et al.
Breast (Edinburgh, Scotland)|March 17, 2022
Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohortFabien Moinard-Butot, Caroline Saint-Martin, Carole Pflumio, et al.
Annals of Surgery|February 3, 2021
Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME CohortJudicaël Hotton, Amélie Lusque, Léa Leufflen, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2019
Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national studyOlivia Le Saux, Audrey Lardy-Cleaud, Sophie Frank, et al.
Therapeutic Advances in Medical Oncology|January 27, 2022
Real-world evidence of the management and prognosis of young women (⩽40 years) with <i>de novo</i> metastatic breast cancerAmélie Mallet, Amélie Lusque, Christelle Levy, et al.
Lancet (London, England)|June 11, 2019
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trialXavier Pivot, Gilles Romieu, Marc Debled, et al.
NPJ Breast Cancer|September 10, 2021
Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancerAmanda Bortolini Silveira, François-Clément Bidard, Marie-Laure Tanguy, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Cancers|February 25, 2023
Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational StudyHélène François-Martin, Audrey Lardy-Cléaud, Barbara Pistilli, et al.
International Journal of Cancer|September 26, 2022
Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world databaseAudrey Mailliez, Veronique D'Hondt, Amelie Lusque, et al.
Therapeutic Advances in Medical Oncology|March 3, 2022
Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME databaseMarcela Carausu, Matthieu Carton, Luc Cabel, et al.
Ebiomedicine|May 8, 2024
Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trialSylvie Giacchetti, Enora Laas, Thomas Bachelot, et al.
Breast (Edinburgh, Scotland)|March 17, 2022
Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohortFabien Moinard-Butot, Caroline Saint-Martin, Carole Pflumio, et al.
Annals of Surgery|February 3, 2021
Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME CohortJudicaël Hotton, Amélie Lusque, Léa Leufflen, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2019
Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national studyOlivia Le Saux, Audrey Lardy-Cleaud, Sophie Frank, et al.
Therapeutic Advances in Medical Oncology|January 27, 2022
Real-world evidence of the management and prognosis of young women (⩽40 years) with <i>de novo</i> metastatic breast cancerAmélie Mallet, Amélie Lusque, Christelle Levy, et al.
Lancet (London, England)|June 11, 2019
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trialXavier Pivot, Gilles Romieu, Marc Debled, et al.
NPJ Breast Cancer|September 10, 2021
Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancerAmanda Bortolini Silveira, François-Clément Bidard, Marie-Laure Tanguy, et al.
Pageof 10